<Anchor>
The Janssen vaccine, which has been discontinued due to side effects of blood clots, is expected to resume in the US soon.
Just like in Europe, it was judged that vaccination was much more beneficial.
The Janssen vaccine is expected to reach 6 million people in Korea.
Reporter Lee Hyun-young.
<Reporter> The
CDC's external advisory body for the Centers for Disease Control and Prevention has recommended resumption of the Janssen vaccine.
According to a study of 15 cases of 8 million Janssen vaccines in the United States who experienced side effects of blood clots, they determined that the benefits of vaccination outweighed the risk.
[Jose Romero/CDC Chairperson of External Advisory Board: In the United States, it is recommended that the Janssen vaccine be given to persons 18 years of age or older.]
However, we have decided to add a warning to the vaccine label stating that women under 50 have an increased risk of thrombosis.
The CDC has stated that it recommends vaccinations for pregnant women as well.
The Janssen vaccine will also be supplied in Korea, and the health authorities will decide on the target and detailed plans through expert advisory meetings.
The competition for vaccines around the world is intensifying.
European Commission Commissioner Ursula von der Leien says he will soon sign an additional supply contract with Pfizer, up to 1.8 billion doses, after a visit to a Pfizer vaccine plant in Belgium.
[Ursula Ponderrayen/EU Executive Chairman: It is expected to sign a contract within a few days to receive 1.8 billion doses over 2021-2023.]
Canada also with Pfizer for the 3rd dose of up to 185 million doses It has been announced that it has entered into an additional purchase agreement to receive a vaccine for use.
(Video editing: Jung Yonghwa)